1. Introduction {#s0005}
===============

Impaired awareness of memory deficits, a.k.a. anosognosia, is a challenging manifestation of Alzheimer\'s disease (AD) that adversely affects the patient\'s safety and decision making and often imposes a negative impact on caregiver quality of life. Anosognosia is a common feature at the AD dementia stage ([@bb0005]), but its prevalence in mild cognitive impairment (MCI), considered to be the prodromal stage of dementia, remains uncertain ([@bb0115]). Some studies report MCI patients have intact insight into their cognitive difficulties ([@bb0060]), while other studies have reported a severe lack of insight ([@bb0040]). Understanding the pathophysiological mechanism underlying impaired awareness of memory deficits in the prodromal stage could help discriminate individuals who are likely to progress to AD dementia from those individuals whose altered awareness of memory is not associated with an underlying pathophysiology.

Although there has been extensive work on the behavioral characterization of anosognosia in AD, (as summarized in a review by [@bb0065]), our knowledge of the neural mechanisms underlying anosognosia remains imprecise and there is no clear-cut consensus on a specific localization of anosognosia. In fact, while anosognosia is a frequent finding in AD dementia, to date relatively few studies have investigated the neuroanatomical correlates of anosognosia in AD dementia ([@bb0055], [@bb0070], [@bb0090], [@bb0095], [@bb0100], [@bb0125], [@bb0130], [@bb0150]) and MCI ([@bb0105], [@bb0110], [@bb0180]). The most common and consistent finding across these studies is the association between anosognosia and dysfunction in prefrontal, including dorsolateral and orbitofrontal regions, as well as in the temporoparietal regions, inferior parietal cortex, posterior cingulate cortex and precuneus. The observation that these findings overlap with brain regions which have been implicated in self-referential processing in normal individuals ([@bb9015], [@bb9020], [@bb9025], [@bb9030]), has led to the proposal that anosognosia may be caused (in part) by the alteration of internally oriented self-related processes ([@bb0085]).

In support for this hypothesis, Perrotin and colleagues recently demonstrated in a group of 23 patients diagnosed with probable AD that anosognosia was related to both functional metabolic changes within cortical midline structures as well as functional disconnections between these cortical midline regions ([@bb0095]). Similarly, Ries and colleagues found, in a mixed group of 12 AD and MCI patients, that individuals with anosognosia showed reduced functional connectivity between the medial prefrontal cortex (PFC) and proximal areas within the medial PFC, dorsolateral PFC and left hippocampus ([@bb0110]).

The present study aims at extending these findings by further our understanding of the brain mechanism underlying anosognosia in the prodromal stage of AD. Thus, we used a multimodal approach consisting of two steps: First, we used regional brain metabolism (18-F fluorodeoxyglucose positron emission tomography (FDG-PET)) to unravel the metabolic correlates of anosognosia in patients with MCI. Thereafter, we used resting state fMRI (rs-fMRI) to investigate the intrinsic connectivity disruption between brain regions using the hypometabolic FDG brain regions as seed regions in our resting state maps. We expected to find functional metabolic changes in brain regions critical for self-assessment and hypothesized that decreased awareness of memory deficits would be related to disruption between these brain regions.

2. Material and methods {#s0010}
=======================

2.1. Subjects {#s0015}
-------------

All subjects were enrolled in an investigator-initiated study at Brigham and Women\'s hospital (BWH) and Massachusetts General Hospital (MGH) in Boston, Massachusetts. Thirty-one patients with amnestic MCI (single or multiple domain) were included in the present study. They all had a mini-mental state exam (MMSE) ([@bb0030]) score of 24--30 (inclusive), a Clinical Dementia Rating (CDR) ([@bb0075]) global score of 0.5 (with memory box score of 0.5 or 1), essentially preserved instrumental activities of daily living (as determined by a clinician), and no evidence of dementia. Of note, subjects with non-amnestic MCI were not eligible to participate in this study.

Two hundred and fifty-one healthy older adults were included as a reference group. To be included as a cognitively healthy older subject, participants had to have an MMSE score of 27--30 (inclusive with educational adjustment), a global CDR score of 0, and perform within normal range on all neuropsychological tests.

Demographic and clinical features of patients and controls are detailed in [Table 1](#t0005){ref-type="table"}.Table 1Demographic and clinical variables.Table 1CNMCIStatistical test*p*-valueN25131CDR00.5Age, y73.3 (6.2)74.3 (7.9)*t* = − 0.810.42Gender, female %58.945.2χ^2^ = 2.20.18Education, y15.7 (3.1)15.7 (3.1)*t* = 8.110.88AMNART120.6 (9.4)119.0 (12.0)*t* = 0.890.37MMSE28.9 (1.1)27.1 (1.9)*t* = 5.38\< 0.001Objective memory13.6 (3.4)6.2 (5.4)*t* = 7.5\< 0.001Subjective memory5.2 (0.9)4.4 (0.9)*t* = 4.8\< 0.001Memory awareness0.07 (1.1)− 0.8 (1.3)*t* = 3.9\< 0.001[^1]

### 2.1.1. Exclusion criteria and consent {#s0020}

Exclusion criteria for all subjects included history of neurologic or major psychiatric disorder, history of head trauma with loss of consciousness, contra-indications for MRI scanning, use of medications that affect cognitive function, severe cardiovascular disease, alcohol or substance abuse, or known cerebrovascular disease (as determined by a Hachinski Ischemia Score ([@bb0120]) higher than 4 and/or presence of cortical infarct, multiple lacunar strokes, or extensive white matter hyperintensities on structural MRI).

This study was approved by and conducted under the auspices of the Partners Human Research Committee at the BWH and MGH (Boston, MA). Informed written consent was obtained from every subject prior to experimental procedures.

2.2. Neuropsychological testing {#s0025}
-------------------------------

### 2.2.1. Objective memory {#s0030}

The Logical Memory IIa of the Wechsler Memory Scale-Revised ([@bb0195]) is a standardized test that assesses immediate and delayed free recall of a short story, consisting of 25 bits of information. The 20 min delayed free recall score was used as the objective memory score for this study, with lower scores indicating greater memory impairment.

### 2.2.2. Subjective memory {#s0035}

The "general frequency of forgetting" subscale of the Memory Functioning Questionnaire ([@bb0045]) was used to assess self-reported memory decline. We used the 18 first questions of this subscale, which contains items regarding everyday situations in which a person would need to use his/her memory. The scale requires participants to rate their memory in terms of the kind of problems they experience on a 7-point scale ranging from 1 ('major problems') to 7 ('no problem'). The scale was transformed to numbers ranging from 0 to 6 and the sum of all 18 questions was used as the subjective memory measure for this study, with lower score indicating greater memory difficulties.

### 2.2.3. Estimation of awareness of memory deficits {#s0040}

Self-awareness was assessed by calculating the discrepancy scores between the objective and subjective measures of memory function. In short, raw scores from objective and subjective measures were converted to z-scores for each subject, using the mean and SD from our control group as the reference group. A delta score was computed by subtracting the subjective memory score from the objective memory score. By this convention, a greater negative value indicates decreased self-awareness of memory functioning or more severe anosognosia.

2.3. Neuroimaging protocols {#s0045}
---------------------------

### 2.3.1. FDG-PET {#s0050}

FDG was acquired for 45--75 min after a 5 to 10 mCi bolus injection in 6 × 5-min frames. To evaluate the anatomy of PET binding, each individual PET data set was rigidly co-registered to the subject\'s MRI data using SPM8 (Wellcome Department of Cognitive Neurology, London). Additional preprocessing steps included spatial normalization to the Montreal Neurological Institute (MNI) space (resampled voxel size 2x2x2mm) using the parameters estimated from the corresponding T1-weighted MRI; and quantitative scaling using the cerebellum grey matter as reference to obtain standardized uptake volume ratio images. The resulting images were used in the correlation analyses with the memory awareness score.

### 2.3.2. Resting state fMRI {#s0055}

All resting-state fMRI data were collected at the Athinoula A. Martinos Center for biomedical imaging in Charlestown, MA on two matched 3 T Trio Tim scanners (Siemens Medical Systems, Erlangen, Germany) using 12-channel phased-array head coils. Scanner noise was attenuated using foam earplugs, and subjects were instructed to lie still, remain awake, and keep eyes open. A functional gradient echo-planar pulse sequence, covering the whole-brain, including the cerebellum, was acquired in the coronal plane using the following parameters: TR = 2500 ms, TE = 30 ms, and FA = 90°, 3.0 mm isotropic voxels. 148 volumes were acquired in each of two 6:10 min runs (including 4 dummy volumes: 10 s). All resting state data were processed using SPM8 (<http://www.fil.ion.ucl.ac.uk/spm/>). The first four volumes of each run were excluded to allow for T1 equilibration. Each run was slice-time corrected, realigned to the first volume of each run with INRIAlign (<http://www-sop.inria.fr/epidaure/software/INRIAlign/>; ([@bb0035])), normalized to the MNI 152 EPI template (Montreal Neurological Institute, Montreal, Canada), and smoothed with a 6 mm FWHM Gaussian kernel. Following these standard preprocessing steps, additional processing known to be beneficial for fcMRI analysis was conducted. These included: (1) regression of realignment parameters (plus first derivatives) to reduce movement artifacts on connectivity, (2) temporal band-pass filtering (second order Butterworth filter) to remove frequencies outside of the 0.01--0.08 Hz band, and (3) nuisance regressors (and their first derivatives) for mean signal from the white matter, lateral ventricles, and global brain signals, with motion parameters were applied ([@bb0160]). For each subject, we created seed-based correlation maps using a 10-mm-diameter spherical seed, located on the maxima of activation identified by the FDG analysis.

2.4. Statistics {#s0060}
---------------

Whole brain voxel-wise SPM t correlation maps were used to examine memory awareness (used as a continuous variable), as a predictor of cerebral glucose metabolic rate (CMR~glc~) metabolism in the MCI patients. Maps were thresholded using a cluster-level FDR correction \< 0.05, corresponding to a *p* = 0.001, k = 115. This threshold was derived using the method described in [@bb0020]. Resulting clusters were used as seed regions in the intrinsic connectivity analysis. Thus, for each of the two seeds obtained from the FDG analysis (right hippocampus and precuneus, see blue areas in [Figs. 3](#f0015){ref-type="fig"}A and B), we created one seed-based connectivity map per subject. We then computed a one-sample *t*-test map (qFDR \< 0.05), investigating which voxels from the whole brain were functionally connected with the seed ([Figs. 3](#f0015){ref-type="fig"}A and B: orange areas). Finally, we regressed the memory awareness score in the connectivity maps (*p* \< 0.050, [Figs. 3](#f0015){ref-type="fig"}A and B: white areas), restricting the results to the voxels significantly connected with the seed, used the resulting map from the previous step, i.e. orange areas, as a mask. Age was entered as a covariate and controlled for in all analyses.

3. Results {#s0065}
==========

3.1. Participants {#s0070}
-----------------

No significant differences were found between CN and aMCI subjects on all demographic variable, except for MMSE scores ([Table 1](#t0005){ref-type="table"}). In the aMCI subjects, no significant relationship was found between the memory awareness score and age (*p* = 0.7); gender (*p* = 0.4), or education (*p* = 0.7). A significant positive relationship was found between memory awareness score and MMSE (*r* = 0.5, *p* = 0.009) indicating that decreased awareness (anosognosia) was related to worse global cognition.

Significant group differences were found for objective and subjective memory scores as well as for the memory awareness score. In comparison to the CN, the aMCI patients had lower objective delayed free recall scores, more subjective memory complaints and decreased memory awareness discrepancy scores (i.e. anosognosia or unaware of their memory deficits; [Table 1](#t0005){ref-type="table"}).

3.2. Relationship between glucose metabolism and anosognosia in MCI patients {#s0075}
----------------------------------------------------------------------------

The whole brain voxel-wise analysis, entering memory awareness discrepancy score as a continuous variable revealed two significant clusters: bilateral posterior midline regions (cluster size: 742) with a peak in precuneus, BA 7 (MNI coordinates: x = 8, y = − 74, z = 32); and right medial temporal lobe (MTL) including hippocampus (cluster size: 115) with a peak in parahippocampus (MNI coordinates: x = 24, y = − 10, z = − 26) ([Fig. 1](#f0005){ref-type="fig"}A).Fig. 1(A) Voxel-wise statistical parametric maps of the significant correlations between FDG-PET uptake and memory awareness discrepancy score in (i) precuneus and (ii) right hippocampus. Maps are controlled at pFDR \< 0.05 using age as covariate. Color bar shows the t-statistics. (B) Bar graphs of the healthy cognitively normal (CN) and mild cognitive impairment (MCI) subjects group comparison on the FDG uptake values in (i) precuneus and (ii) hippocampus. \*\*\* = *p* \< 0.001. (C) Plot of the correlations between FDG uptake in (i) precuneus and (ii) hippocampus and the memory awareness discrepancy score in MCI patients. *P*-values are 2-tailed. Lower score represent less awareness (anosognosia).Fig. 1

Post hoc analysis revealed significantly reduced glucose metabolism in the MCI patients as compared to CN individuals (indicating that these areas are hypometabolic in MCI patients) ([Fig. 1](#f0005){ref-type="fig"}B). In the MCI patients, a significant positive correlation between memory awareness and glucose metabolism was found, such that decreased awareness (anosognosia) was related to lower glucose metabolism in these regions ([Fig. 1](#f0005){ref-type="fig"}C).

3.3. Reduced intrinsic connectivity with Anosognosia in MCI patients {#s0080}
--------------------------------------------------------------------

To investigate whether functional connectivity of a network involving the precuneus and hippocampus was related to anosognosia in our MCI patients, we used the hypometabolic brain regions we had found with FDG-PET as our seed regions and entered memory awareness as a covariate (see [Fig. 3](#f0015){ref-type="fig"}A, purple area). Using the FDG-PET precuneus seed in the intrinsic connectivity analysis (*p* \< 0.05, cluster extent = 5 voxels, controlling for age), we found significant positive correlations between the bilateral inferior parietal lobes (IPL); left posterior cingulate cortex (PCC); and the orbitofrontal cortex (OFC). In all these regions, decreased memory awareness was significantly related to decreased functional connectivity ([Fig. 2](#f0010){ref-type="fig"}A and C). Using the FDG-PET right hippocampus seed in the intrinsic connectivity analysis (*p* \< 0.05, cluster extent = 5 voxels, controlling for age; [Fig. 3](#f0015){ref-type="fig"}B, purple area), we found significant correlations between several brain regions in the left MTL, as well as in right fusiform gyrus. In all these regions, decreased memory awareness was significantly related to decreased functional connectivity ([Fig. 2](#f0010){ref-type="fig"}B and D).Fig. 2(A) Intrinsic connectivity maps (*p* = 0.05, cluster extent = 5, controlling for age) between the precuneus seed region and the orbitofrontal cortex (OFC), left posterior cingulate cortex (PCC), and bilateral inferior parietal loves (IPL; circled) and between Color bar shows the t-statistics. (B) right hippocampus seed region and the left medial temporal lobe including hippocampus (circled). (C) Plot of the correlation between the intrinsic connectivity using the precuneus as seed region in the significant clusters and the memory awareness score. (D) Plot of the correlation between the intrinsic connectivity using the right hippocampus as seed region in the significant clusters. *P*-values are two-sided. Lower score represent decreased awareness (anosognosia).Fig. 2Fig. 3Overlay of the awareness-FDG-PET and awareness-intrinsic connectivity maps (color coded in white and purple) on top of the intrinsic connectivity map for the (A) PCC seed region respectively (B) MTL seed region elicited in the MCI patients (orange). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 3

4. Discussion {#s0085}
=============

The present study investigated the brain mechanism underlying unawareness of memory deficits by combining measures of regional brain metabolism (as measured with FDG-PET) and intrinsic connectivity (as measured with resting state fMRI). Our results demonstrate that decreased awareness of memory deficits (anosognosia) in aMCI subjects is related to FDG hypometabolism in precuneus and hippocampus. Furthermore, using the hypometabolic regions as seed regions, we found that functional disconnections between cortical midline regions were related to increased anosognosia. These results provide further evidence and support the hypothesis that anosognosia may be the result of both functional metabolic changes and functional disconnection between brain regions supporting self-referential processing as well as memory processing.

Our findings of decreased awareness of memory deficits in aMCI, as compared to CN, provide further evidence supporting the finding that anosognosia is present in the prodromal stages of AD ([@bb0115]). Further, our finding of a positive relationship between memory awareness and MMSE score is in line with previous studies of AD patients which indicate that anosognosia correlates with overall disease severity ([@bb0060]).

The results of our voxel-wise correlations between the memory awareness discrepancy score and FDG-PET data were consistent with our hypothesis to find functional metabolic changes in brain regions critical for self-assessment. FDG-PET imaging is suggested to directly reflect neural activity at rest and provides an index of functional integrity ([@bb0140]). Thus, our findings of decreased glucose metabolism in the precuneus and hippocampus, which was hypometabolic relative to the CN sample, provides further evidence that anosognosia is in part due to compromise to brain regions critical for retrieval and manipulation of autobiographical episodic memories, and more recently self-referential processing. ([@bb0010], [@bb0205]). For instance, previous work investigating successful retrieval has shown greater activation in the posteromedial cortices in proportion to the strength or certainty of the memory decision ([@bb0155], [@bb0185]). Similarly, previous studies have shown that these regions are involved in subjective judgments about memory retrieval, including "remember vs. know" assessments and metamemory processes, such as postretrieval confidence ratings ([@bb0015], [@bb0200]).

In a fMRI study, [@bb0105] reported decreased neuronal activation during a self-referencing task in the posterior cingulate and medial prefrontal cortex in MCI subjects who were less aware of their own deficits. Our results are in line with [@bb0095], who found that anosognosia in AD dementia patients was associated with hypometabolism (using FDG-PET) in posterior cingulate cortices. These results also converge with our recent work investigating the metabolic correlates of subjective memory complaints in cognitively normal older adults. Using a similar voxel-wise approach we entered subjective memory complaints into whole brain correlation maps and found that increased complaints were related to decreased glucose metabolism in the cortical midline regions ([@bb0170]). Since these individuals were cognitively normal at the time of testing, their memory complaints would indicate heightened awareness of their memory ability ([@bb0165]). Indeed, it has recently been proposed by our group ([@bb0165]), as well as by [@bb0025], that the level of self-awareness varies in a continuum from normal awareness of cognitive performance to anosognosia through a phase in which the individual experiences awareness of normal performance as impaired. Our findings of reduced hippocampal metabolism in individuals with increased anosognosia are somewhat concurrent with previous studies demonstrating decreased hippocampal metabolism in prodromal AD ([@bb0050], [@bb0080]). Interestingly, in our previous study we found that cognitively normal individuals with increased cortical amyloid burden and increased complaints (heightened awareness) had decreased FDG metabolism in the hippocampus, providing further evidence that the functional disturbance of this region may be a specific marker of changes in awareness encompassing both the preclinical and prodromal stage of AD ([@bb0170]).

Furthermore, and in line with [@bb0095], by using resting state fMRI and the PCC as seed regions, we found a significant association between anosognosia and attenuated functional connectivity between the PCC seed region and OFC, as well as bilateral IPL. These results provide further evidence that disconnection between the PCC and OFC may reflect a disruption of the white matter fiber pathways making up the cingulum bundle ([@bb0175]). In contrast to Perrotin et al.'s work, we did not find a relationship between our PCC seed region and the medial temporal lobe. This discrepancy might be due to the fact that Perrotin and colleagues investigated individuals with AD dementia who are likely to be further along the pathological trajectory of AD. Future studies looking at the either the baseline difference between MCI and AD dementia patients or at longitudinal changes within subjects on the trajectory of AD may further clarify the pathophysiology underlying anosognosia at different stages of the disease. Nonetheless, the findings of disconnection within the cortical midline regions support the hypothesis that anosognosia is caused by alteration of internally oriented self-related processes ([@bb0135]). Thus, it can be argued that the disconnection with the self-referential regions might impair the metamnemonic monitoring processes necessary to update the person\'s knowledge about their memory skills.

In contrast to our expectations as well as with previous studies, such as ([@bb0095]), we did not find a reduced functional connectivity between hippocampus and the OFC or PCC. We did, however, find reduced functional connectivity between the left and right hippocampus (using the FDG-PET right hippocampus as our seed region) in individuals with reduced awareness. Previous studies investigating hippocampal connectivity in AD dementia patients have reported diminished hippocampal connectivity in AD dementia patients when compared to healthy controls who instead present rightward asymmetry between the two hippocampi ([@bb0190]). Future studies on the specific relationship between hippocampal connectivity and the relationship with awareness are needed to disentangle these results. Also, inclusion of a sample with AD dementia patients might shed some further light on this.

We acknowledge that there are several limitations to this study. First, there is no consensus on how to optimally assess anosognosia in AD (see [@bb0145]). The primary methods being (1) clinical judgment, (2) comparison of study partner to informant reports, and (3) comparison of participants\' self-assessment and task performance. Here we used the third approach, which has been suggested to present an advantage in that it is comparing a subjective memory report to an objective gold standard. As this method was used by [@bb0095], we also opted for this approach to be able to more easily compare our results to their results. Future studies will utilize other subjective memory questionnaires to investigate potential discrepancies between the subject\'s self-report and the report of the informant to get further insight into the self-awareness of these memory problems in our participants and how that is related to FDG metabolism and functional connectivity. In addition, we acknowledge that this was a cross-sectional study and that longitudinal studies will be necessary to determine whether our findings may serve as a relevant predictor of AD progression.

5. Conclusions {#s0090}
==============

By combining measures of regional brain metabolism (as measured with FDG-PET), and intrinsic connectivity (as measured with resting state fMRI), we found that decreased awareness of memory deficits (anosognosia) in aMCI patients may be the result of both functional metabolic changes, as well as a functional disconnection between brain regions supporting self-referential processing and memory processing. Investigating neuroimaging changes that co-vary with memory awareness may improve our ability to identify and understand the cause of anosognosia and ultimately increase our chances for its treatment.
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[^1]: Mean and standard deviation (SD). AMNART = American National Adult Reading Test; CDR = clinical dementia rating; CN = cognitively normal; MCI = Mild cognitive impairment, MMSE = Mini-Mental State Examination; y = years.
